The FDA has rejected Aldeyra Therapeutics’ application for reproxalap, an investigational treatment for dry eye disease, citing a lack of substantial evidence that the drug is effective.
In a Complete Response Letter, the agency said inconsistent study results raised concerns about the reliability of the drug’s clinical findings, according to a March 17 company statement. While no safety or manufacturing issues were identified, the FDA concluded the totality of evidence did not support approval.
The FDA recommended further exploration into why certain trials failed and whether specific patient populations may benefit but did not request new studies or additional confirmatory data. Aldeyra said it does not plan to conduct more clinical trials and will request a Type A meeting to clarify next steps.
Label drafts were exchanged with the FDA in December 2025 and March 2026, but Aldeyra said negotiations were not completed.
As of Dec. 31, 2025, the company reported $70 million in cash, cash equivalents and marketable securities and said it expects the funds will support operations into 2028.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
